Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome
World Journal of Surgical Oncology · 2024
DOI: 10.1186/s12957-024-03463-w ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgical Oncology, 2024. Verfasst von Haiping Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: ErbB Receptors, Oncogene Proteins, Fusion, Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Epidermal growth factor receptor ( EGFR) fusions are rare but potentially actionable oncogenic drivers across multiple solid tumors. However, the distribution and molecular characteristics of EGFR fusions in Chinese patients with solid malignancies have not been explored.
Methods
Panel-based next-generation sequencing (NGS) data of 35,023 patients with various types of solid tumors was collected and analyzed from the Simcere Diagnostics (Nanjing, China) database. A 9563-patient cohort was derived from The Cancer Genome Atlas (TCGA) to explore the relationship between EGFR fusion status and overall survival (OS).
Results
In this study, prevalence of functional EGFR fusions was 0.303% (106/35,023) in total across solid tumors, which occur more commonly in gastroesophageal junction cancer (1/61, 1.613%), followed by medulloblastoma (1/66, 1.515%) and glioma (33/2409, 1.370%). Analysis showed a prevalence for fusion partners in different tumor types. The top 3 co-mutant genes with EGFR fusion were TP53 (mutation frequency, MF: 65%), BRCA2 (MF: 43%), and ALK (MF: 41%). Furthermore, patients in the EGFR fusion group had a significantly shorter OS than those in the non- EGFR fusion group ( p < 0.0001) in the TCGA cohort, suggesting that EGFR fusion might be a high-risk factor for poor prognosis.
Conclusions
Our study is the first retrospective analysis of EGFR fusions in a large-scale solid tumor population, which may provide a reference for future EGFR-TKI clinical trials with EGFR fusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
- Department of Neurosurgery, Second Affiliated Hospital of Air Force Military Medical University, Xi'an, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China.
- Department of Thoracic Oncology, Linfen Center Hospital, Linfen, China.
- Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
- Health Education Promotion Department, Shenyang Stomatological Hospital, Shenyang, China.
Zitieren
APA
Zhang, H., Wang, J., Li, X., Zhang, D., Qi, Y., Zhang, Q., Luo, N., Wang, X., & Wang, T. (2024). Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome. World Journal of Surgical Oncology. https://doi.org/10.1186/s12957-024-03463-w
Vancouver
Zhang H, Wang J, Li X, Zhang D, Qi Y, Zhang Q, et al. Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome. World Journal of Surgical Oncology. 2024. doi:10.1186/s12957-024-03463-w
BibTeX
@article{Zhang2024,
author = {Zhang, Haiping and Wang, Julei and Li, Xiaoxiao and Zhang, Dongfeng and Qi, Yingxue and Zhang, Qin and Luo, Ningning and Wang, Xiaoou and Wang, Tuo},
title = {Distribution of EGFR fusions in 35,023 Chinese patients with solid tumors-the frequency, fusion partners and clinical outcome},
journal = {World Journal of Surgical Oncology},
year = {2024},
doi = {10.1186/s12957-024-03463-w}
}
EUVIMED